Meningococcal polysaccharide vaccine group A

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Brand Names
Menquadfi, Menveo, Nimenrix
Generic Name
Meningococcal polysaccharide vaccine group A
DrugBank Accession Number
DB13889
Background

Meningococcal group A polysaccharide is group-specific polysaccharide antigens extracted and purified from Neisseria meningitidis serogroup A. N. meningitidis is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup A.

Type
Biotech
Groups
Approved, Experimental, Investigational
Biologic Classification
Vaccines
Other vaccines
Synonyms
  • Meningococcal group A polysaccharide
  • Meningococcal polysaccharide antigen group A
  • Neisseria meningitidis group A capsular polysaccharide antigen
  • Neisseria meningitidis group A polysaccharide antigen, A

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
MENACTRA 0,5 ML IM ENJEKSİYONLUK ÇÖZELTİ İÇEREN FLAKON, 1 ADETMeningococcal polysaccharide vaccine group A (4 mcg/0.5ml) + Meningococcal polysaccharide vaccine group C (4 mcg/0.5ml) + Meningococcal polysaccharide vaccine group W-135 (4 mcg/0.5ml) + Meningococcal polysaccharide vaccine group Y (4 mcg/0.5ml)Injection, solutionIntramuscularSANOFİ PASTEUR AŞI TİC. A.Ş.2020-08-14Not applicableTurkey flag
MENACTRA 0,5 ML IM ENJEKSİYONLUK ÇÖZELTİ İÇEREN FLAKON, 5 ADETMeningococcal polysaccharide vaccine group A (4 mcg/0.5ml) + Meningococcal polysaccharide vaccine group C (4 mcg/0.5ml) + Meningococcal polysaccharide vaccine group W-135 (4 mcg/0.5ml) + Meningococcal polysaccharide vaccine group Y (4 mcg/0.5ml)Injection, solutionIntramuscularSANOFİ PASTEUR AŞI TİC. A.Ş.2020-08-14Not applicableTurkey flag
Mencevax Ac Pws 500mcg/vialMeningococcal polysaccharide vaccine group A (500 mcg / vial) + Meningococcal polysaccharide vaccine group C (500 mcg / vial) + Sodium chloride (5 mL / vial)Powder, for solutionSubcutaneousGlaxosmithkline Inc1994-08-292006-06-02Canada flag
Mencevax Ac Pws 50mcg/vialMeningococcal polysaccharide vaccine group A (50 mcg / vial) + Meningococcal polysaccharide vaccine group C (50 mcg / vial) + Sodium chloride (.5 mL / vial)Powder, for solutionSubcutaneousGlaxosmithkline Inc1992-12-312006-06-02Canada flag
Mencevax Ac Pws Inj 2500mcg/vialMeningococcal polysaccharide vaccine group A (2.5 mg / vial) + Meningococcal polysaccharide vaccine group C (2.5 mg / vial) + Sodium chloride (25 mL / vial)Powder, for solutionSubcutaneousGlaxosmithkline Inc1992-12-312006-06-02Canada flag
MENCEVAX ACWY 0,5 ML SC ENJEKSİYON İÇİN LİYOFİLİZE TOZ İÇEREN ÇOK DOZLU FLAKON, 50 ADETMeningococcal polysaccharide vaccine group A (50 mcg/0.5ml) + Meningococcal polysaccharide vaccine group C (50 mcg/0.5ml) + Meningococcal polysaccharide vaccine group W-135 (50 mcg/0.5ml) + Meningococcal polysaccharide vaccine group Y (50 mcg/0.5ml)Injection, powder, for solutionSubcutaneousPFİZER PFE İLAÇLARI A.Ş.2020-08-142019-07-01Turkey flag
Meningococcal Polysaccharide Vaccine Groups A & CMeningococcal polysaccharide vaccine group A (500 mcg / vial) + Meningococcal polysaccharide vaccine group C (500 mcg / vial)Kit; Powder, for solutionSubcutaneousAventis Pasteur Sa1998-08-132007-08-14Canada flag
Menomune - A/c/y/w-135 CombinedMeningococcal polysaccharide vaccine group A (50 ug/0.5mL) + Meningococcal polysaccharide vaccine group C (50 ug/0.5mL) + Meningococcal polysaccharide vaccine group W-135 (50 ug/0.5mL) + Meningococcal polysaccharide vaccine group Y (50 ug/0.5mL)SubcutaneousSanofi Pasteur Inc.1981-11-232017-09-10US flag
Menomune-A/c/y/w-135Meningococcal polysaccharide vaccine group A (500 mcg / kit) + Meningococcal polysaccharide vaccine group C (500 mcg / kit) + Meningococcal polysaccharide vaccine group W-135 (500 mcg / kit) + Meningococcal polysaccharide vaccine group Y (500 mcg / kit)Powder, for solutionSubcutaneousSanofi Pasteur Limited1983-12-312017-04-05Canada flag
Menomune-A/c/y/w-135Meningococcal polysaccharide vaccine group A (50 mcg / 0.5 mL) + Meningococcal polysaccharide vaccine group C (50 mcg / 0.5 mL) + Meningococcal polysaccharide vaccine group W-135 (50 mcg / 0.5 mL) + Meningococcal polysaccharide vaccine group Y (50 mcg / 0.5 mL)Kit; Powder, for solutionSubcutaneousSanofi Pasteur Limited1993-10-292017-04-05Canada flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
1I86B47NY4
CAS number
Not Available

References

General References
Not Available
PubChem Substance
347911458
RxNav
29501
FDA label
Download (83.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingPreventionMeningococcal Disease, Invasive1
4Active Not RecruitingPreventionPapillomavirus Infections1
4CompletedBasic ScienceMeningitis / Meningococcal Disease / Septicemia1
4CompletedPreventionMeningococcal Disease1
4CompletedTreatmentImmunizations / Meningitis / Pertussis / Preventive Immunization; Meningitis1
4RecruitingOtherMeningococcal Meningitis1
4RecruitingPreventionHuman Immunodeficiency Virus (HIV) Infections / Meningococcal Infections / Pneumococcal Infection1
3CompletedPreventionBacterial Infections / Neisseria Meningitidis / Virus Diseases1
3CompletedPreventionMeningitis / Meningococcal Infections / Meningococcal Meningitis1
3CompletedPreventionMeningitis / Septicemia1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, solutionIntramuscular
Powder, for solutionSubcutaneous
Injection, powder, for solutionSubcutaneous
Kit; powder, for solutionSubcutaneous
PowderIntramuscular
Powder, for solution; solutionIntramuscular
Injection, powder, lyophilized, for solutionIntramuscular
Kit; powder, for solutionIntramuscular
Injection, powder, for solutionIntramuscular
Injection, powder, for solution
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on September 08, 2017 20:22 / Updated on June 12, 2020 16:53